

TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

11/26/2015; Page 1

	Folic Acid 1 mg Oral Disintegrating Tablets (Solid Suspension, 100 x 0.125 in [0.151 mL] Tablets)	FIN	F 006 593
--	---	-----	-----------

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC#	Supplier	Lot Number	Expiry Date
Folic Acid, USP	TBD					
Mango Flavor (Powder)	0.13	g				
Raspberry Flavor (Powder)	0.07	g				
Vanillin Flavor (Powder)	0.03	g				
Stevia Powder	0.015	g				
F-MELT® (Type C) Base	TBD		8)		

SPECIAL PREPARATORY CONSIDERATIONS

<u>Ingredient-Specific Information</u>					
Light sensitive (protect from lig	ght whenever possible):	Folic Acid			
Hygroscopic (protect from moi	sture whenever possible):	F-MELT® (Type C), Stevia Powder			
Suggested Preparatory Guidelines					
Non-Sterile Preparation Sterile Preparation					
<u>Processing Error /</u> Testing Considerations:	1	and considerations during preparation, it is suggested of the required quantities of ingredients.			
Special Instruction:		eoat, disposable gloves, eyewear and face-masks			
		f very small quantities of ingredients. All calculations be verified before dispensing the final product.			



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

11/26/2015; Page 2

	Folic Acid 1 mg Oral Disintegrating Tablets (Solid Suspension, 100 x 0.125 in [0.151 mL] Tablets)	FIN	F 006 593
--	---	-----	-----------

SUGGESTED PREPARATION (for 100 Tablets)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*):	Processing Error	Qty. to measure
Folic Acid, USP §	TBD				
Mango Flavor (Powder)	0.13	g			
Raspberry Flavor (Powder)	0.07	g			
Vanillin Flavor (Powder)	0.03	g	(C)		
Stevia Powder §	0.015	g			
F-MELT® (Type C) Base §	TBD		, Y C .		

- * Takes into account increased batch size conversions and density conversions, if required.
- § Weigh / measure just prior to use.

A. Determine the potency of Folic Acid based on the certificate of analysis:	
A. Determine the potency of Fone Acid based on the certificate of analysis.	
MINITIE	100%
MINUS Water Content (from certificate of analysis)	9,
DIVIDED BY	100
EQUALS	
Quantity of water free Folic Acid, in decimal	
MULTIPLIED BY	
Assay on anhydrous basis result (from certificate of analysis)	
DIVIDED BY	100
EQUALS	



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

11/26/2015; Page 3

	ggested ormula	Folic Acid 1 mg Oral Disintegrating Tablets (Solid Suspension, 100 x 0.125 in [0.151 mL] Tablets)	FIN	F 006 593
2.	Ingr	edient quantification:		
	A. I	Determine the quantity (in g) of Folic Acid required to make 100 Tablets of Folic Acid 1	mg:	
	(Quantity of Folic Acid needed for each tablet		0.001 g
	I	DIVIDED BY		
	I	Potency of Folic Acid, in decimal (Step 1Ai)	_	
	1	EQUALS		
	i	. Actual Quantity of Folic Acid needed for each tablet	_	g
	1	MULTIPLIED BY		
	1	Number of tablets		100
	1	MULTIPLIED BY		
	I	Processing error adjustments (5 to 9%)	1	.05 to 1.09
	I	EQUALS		
	i	i. Total Quantity of Folic Acid needed <i>plus</i> processing error adjustments	_	g
3.	Colo	ulate the quantity of F-MELT® (Type C) Base required for 100 x 0.125 in [0.151 mL	1 Tob	lots.
3.			<u> </u>	ieis.
	A. I	Determine the average Die fill weight by filling and weighing a TARED Die with the F-MELT® (Type C) Base, five times . Divide the total weight by 5 to obtain <u>average</u> weight	ght	g (A)
		Quantity of F-MELT® (Type C) Base required per Die = $(A) - (Step 2Ai^* + 0.00245 g)$ quantity of Folic Acid per tablet.	-	g (B)
	C. 7	Total quantity of F-MELT® (Type C) Base required for the batch = (B) x 100 Tablets	_	g (C)
	D. (Quantity of F-MELT® (Type C) Base to weigh with processing error = (C) x $1.05 \sim 1.09$	_	g (D)



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

11/26/2015; Page 4

	Folic Acid 1 mg Oral Disintegrating Tablets (Solid Suspension, 100 x 0.125 in [0.151 mL] Tablets)	FIN	F 006 593
--	---	-----	-----------

4. **Powder preparation:**

- A. Pass the F-MELT[®] (Type C) Base through a 40 or 50 mesh sieve and weigh the required quantity (**D**).
- B. By geometric addition, combine and triturate the following ingredients together to form a fine, homogeneous powder blend:
 - -Folic Acid (amount determined in Step 2Aii)
 - -Mango Flavor (Powder)
 - -Raspberry Flavor (Powder)
 - -Vanillin Flavor (Powder)
 - -Stevia Powder
- C. By geometric addition, combine and mix, using a manual tumbler mixer, (DO NOT TRITURATE) the following ingredients together to form a homogeneous powder blend:
 - -Sieved F-MELT® (Type C) Base (Step 4A)
 - -Homogeneous powder blend (Step 4B)

5. **Mold filling:**

- A. **Fill the die**: Set the die and its holder on the base of the press with the beveled edge of the die resting on the flat surface in the reversible holder. Pour the charge into the die cavity and tamp with a stirring rod, if necessary.
- B. Compress the charge: Transfer the die and its holder to the press and push the lever down to compress the charge. To obtain maximum compression, the lever should require a firm push as it moves through its full stroke. If a full stroke is not obtained, turn the anvil to lower or raise the die until the full mechanical advantage of the press can be utilized.
- C. **Reverse the die holder**: Raise the lever and slide the die and its holder out of the press. Reverse the holder to bring the deep cavity under the die and return the parts to their original position.
- D. **Eject the pellet**: Bring the lever down gently to eject the pellet into the cavity in the holder. If a thick pellet is not ejected by this stroke, turn the anvil to raise the die. The pellet will then drop out freely. Remove the pellet with tweezers or forceps; reverse the holder and **repeat the cycle if additional tablets are required.**

6. Validation technique:

- A. Weigh 20 tablets separately.
- B. The final weight of each tablet should fall between 90 and 110% of the theoretically calculated weight (A), in accordance to USP 795 guidelines.

7. **Product transfer:**

Transfer the final product into the specified dispensing container (see "Packaging Requirements").



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

11/26/2015; Page 5

	Folic Acid 1 mg Oral Disintegrating Tablets (Solid Suspension, 100 x 0.125 in [0.151 mL] Tablets)	FIN	F 006 593
--	---	-----	-----------

SUGGESTED PRESENTATION

U	GGESTED PRESENTATION							
	Estima Beyond-Use D		6 months, as per USP*.	Packag Requireme		Tightly closed, light-resistant vials.		
		1	Use as directed. Do not exceed dose.	d prescribed	5	Keep in a dry place.		
		2	Keep out of reach of children.		6	Keep at room temperature (20°C – 23°C).		
	Auxiliary Labels	3	Cap tightly after use.		7	Consult your health care practitioner if any prescription or over-the-counter medications are currently being used or are prescribed for future use.		
		4	Protect from light.					
Pharmacist Instructions Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.						ensing container as deemed necessary.		
	Patient Instructions	Contact your pharmacist in the event of adverse reactions						

^{*} The BUD is not later than the time remaining until the earliest expiration date of any API or 6 months, whichever is earlier.



TELEPHONE: 514-905-5096 FAX: 514-905-5097 technicalservices@medisca.net

11/26/2015; Page 6

	Folic Acid 1 mg Oral Disintegrating Tablets (Solid Suspension, 100 x 0.125 in [0.151 mL] Tablets)	FIN	F 006 593
--	---	-----	-----------

REFERENCES

 	LNCLS
1.	Tablets. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding Fourth Edition.</i> American Pharmaceutical Association; 2012: 175.
2.	Ferralet 90. In: <i>Physicians Desk Reference</i> ®. Montvale, NJ: Thomson PDR; 2015: 1792.
3.	Folic Acid. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference</i> , 36 th Edition. London, England: The Pharmaceutical Press; 2009: 1940.
4.	Folic Acid (Monograph). In: O'Neil MJ. <i>The Merck Index 15th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2013: Monograph #4248.
5.	Folic Acid. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations</i> , 5 th Edition. American Pharmaceutical Association; 2012: 216.
6.	Folic Acid (Monograph). <i>United States Pharmacopeia XXXVIII / National Formulary 33</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2015: 3601.
7.	Folic Acid Systemic. Thomson Micromedex. <i>USP DI – Drug Information for the Health Care Professional, 26th Edition.</i> Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 1537.
8.	USP <795>. <i>United States Pharmacopeia XXXVIII / National Formulary 33</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2015: 559.

DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.